• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

ABO exam phase-in application ends April 30


Interested in becoming ABO certified? Qualifications will change at the end of the month.

The American Board of Optometry (ABO) reminds optometrists that as of April 30, qualifying for the ABO exam under the rules of the 3-year phase-in period expires.

ODs can still become board certified after the phase-in period ends. However, effective May 1, Experience in Active Clinical Practice and Fellowship in the College of Optometrists in Vision Development will no longer be accepted as part of the qualification. Requirements for Category 1 and 2 Education will remain unchanged.

To qualify under the rules of the phase-in period, candidates must complete the following:

•    Apply to become an active candidate no later than April 30.

•    Submit their post-graduate requirements for verification by the ABO no later than June 30.

•    Take the ABO Board Certification Examination no later than January 2014, date of the last exam using phase-in rules.

For more information, visit the ABO Web site at www.americanboardofoptometry.org or e-mail info@abopt.org.

Related Videos
R Tracy Williams, OD, FAAO, tells his favorite stories as a team optometrist for the Chicago Bulls, White Sox
R Tracy Williams, OD, FAAO, details his experience as a sports team optometrist
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
© 2024 MJH Life Sciences

All rights reserved.